RA patients had decreased CD4 cell expression (both VZV-specific and SEB-like) compared to the control group and thus showed signs of impaired cellular immunity. Patients treated with biological DMARDs had the most devastating impact on their cellular immunity. This evidence concerns the gene CD4 and rheumatoid arthritis.